These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 17576527

  • 1. [Costs involved in the early and late phases of diabetes mellitus].
    Liebl A.
    Internist (Berl); 2007 Jul; 48(7):708-14. PubMed ID: 17576527
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
    Schädlich PK, Koltermann KC, Dippel FW, Hagenmeyer EG, Häussler B.
    MMW Fortschr Med; 2010 Oct 14; 152 Suppl 3():89-95. PubMed ID: 21595152
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study].
    Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Görtz A.
    Dtsch Med Wochenschr; 2001 May 18; 126(20):585-9. PubMed ID: 11402924
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S.
    Appl Health Econ Health Policy; 2016 Jun 18; 14(3):281-92. PubMed ID: 26961276
    [Abstract] [Full Text] [Related]

  • 7. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
    Gallwitz B.
    MMW Fortschr Med; 2014 Jul 24; 156(13):57-60. PubMed ID: 25318228
    [No Abstract] [Full Text] [Related]

  • 8. [Cost of diabetes mellitus in Spain].
    González P, Faure E, Del Castillo A, Grupo de Trabajo para el Estudio del Coste de la Diabetes.
    Med Clin (Barc); 2006 Nov 25; 127(20):776-84. PubMed ID: 17198665
    [No Abstract] [Full Text] [Related]

  • 9. [Obesity and diabetes mellitus: increasing problems call for increasing efforts].
    Nauck M.
    Dtsch Med Wochenschr; 2010 May 25; 135(18):901. PubMed ID: 20425673
    [No Abstract] [Full Text] [Related]

  • 10. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
    Yeaw J, Halinan S, Hines D, Delozier A, Perez M, Boye M, Boye KS, Blanchette CM.
    Appl Health Econ Health Policy; 2014 Apr 25; 12(2):219-30. PubMed ID: 24573912
    [Abstract] [Full Text] [Related]

  • 11. [New, expensive antidiabetics for the treatment of type-2 diabetes--contra].
    Nawroth P.
    Dtsch Med Wochenschr; 2010 May 25; 135(18):923. PubMed ID: 20425679
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system.
    Bahia LR, Araujo DV, Schaan BD, Dib SA, Negrato CA, Leão MP, Ramos AJ, Forti AC, Gomes MB, Foss MC, Monteiro RA, Sartorelli D, Franco LJ.
    Value Health; 2011 May 25; 14(5 Suppl 1):S137-40. PubMed ID: 21839888
    [Abstract] [Full Text] [Related]

  • 15. [Diabetes disease management program. What is its purpose?].
    Stoschek J.
    MMW Fortschr Med; 2006 May 11; 148(19):49, 51. PubMed ID: 16736710
    [No Abstract] [Full Text] [Related]

  • 16. Determinants of diabetes-attributable non-blood glucose-lowering medication costs in type 2 diabetes: the Fremantle Diabetes Study.
    Davis WA, Knuiman MW, Hendrie D, Davis TM.
    Diabetes Care; 2005 Feb 11; 28(2):329-36. PubMed ID: 15677788
    [Abstract] [Full Text] [Related]

  • 17. [Prevention and early therapy play too minor a role in our health care system].
    Rothe HJ.
    Med Klin (Munich); 2003 Oct 15; 98 Suppl 1():22-3. PubMed ID: 14694840
    [No Abstract] [Full Text] [Related]

  • 18. Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania.
    Domeikienė A, Vaivadaitė J, Ivanauskienė R, Padaiga Ž.
    Medicina (Kaunas); 2014 Oct 15; 50(1):54-60. PubMed ID: 25060205
    [Abstract] [Full Text] [Related]

  • 19. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study.
    Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G, CODE-2 Italian Advisory Board.
    Treat Endocrinol; 2003 Oct 15; 2(2):121-33. PubMed ID: 15871548
    [Abstract] [Full Text] [Related]

  • 20. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
    van der Linden MW, Plat AW, Erkens JA, Emneus M, Herings RM.
    Value Health; 2009 Sep 15; 12(6):909-14. PubMed ID: 19508664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.